Transarterial Chemoembolization

Transarterial Chemoembolization Market Outlook

The global Transarterial Chemoembolization (TACE) market is projected to reach USD 4.5 billion by 2035, expanding at a CAGR of 12.4% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of liver cancers, particularly hepatocellular carcinoma, coupled with advancements in interventional radiology techniques and a growing focus on minimally invasive procedures. The rising demand for effective cancer treatment options, especially in regions with high liver cancer incidence, is also influencing market dynamics. Furthermore, the growing number of clinical trials and research initiatives aimed at optimizing TACE procedures is expected to contribute significantly to market growth over the coming years. The integration of advanced embolic agents and the adoption of innovative catheter technologies are anticipated to enhance treatment outcomes and expand the patient population eligible for TACE, thereby driving further market expansion.

Growth Factor of the Market

Several factors are propelling the growth of the Transarterial Chemoembolization market. The increasing incidence of liver diseases, particularly liver cancer, is a primary driver, as TACE is a common treatment modality for such conditions. Additionally, advancements in imaging technologies, such as MRI and CT scans, have improved the precision of TACE procedures, ensuring better outcomes for patients. The rising awareness among healthcare professionals about the benefits of TACE over traditional surgical interventions is also a crucial factor. Moreover, the introduction of novel embolic agents and chemotherapy drugs specifically designed for TACE has expanded the range of treatment options available, thus attracting a larger patient base. Furthermore, government initiatives aimed at enhancing cancer care and funding for research into innovative cancer therapies are expected to further bolster the market.

Key Highlights of the Market

• The TACE market is expected to grow at a CAGR of 12.4% between 2025 and 2035.
• Hepatocellular carcinoma is the leading application segment, accounting for a significant share of the market.
• North America holds the largest market share due to advanced healthcare infrastructure and high treatment adoption rates.
• Emergence of new embolic agents and advancements in catheter technology are driving innovation in TACE.
• Growing emphasis on minimally invasive procedures is shaping the future of liver cancer treatment.

By Product Type

Chemotherapy Drugs:

Chemotherapy drugs play a pivotal role in the transarterial chemoembolization procedure, as they are administered directly into the tumor site. The most commonly used drugs include doxorubicin and cisplatin, which have shown efficacy in targeting liver tumors. The demand for chemotherapy drugs in the TACE market is on the rise due to their ability to induce tumor necrosis and reduce tumor size, which is critical in managing complex liver cancers. Ongoing research into more effective chemotherapeutic agents, including targeted therapies, is anticipated to further enhance the efficacy of TACE procedures. As a result, the chemotherapy drugs segment is expected to witness significant growth, driven by continuous advancements in drug formulations and increased awareness of TACE as a treatment option.

Embolic Agents:

The embolic agents segment is crucial for the success of the TACE procedure, as these agents are used to occlude blood vessels feeding the tumor, thereby cutting off its blood supply. Various embolic agents, such as gelatin sponge, polyvinyl alcohol (PVA) particles, and microspheres, are utilized based on the tumor characteristics and the physician’s preference. The market for embolic agents is experiencing robust growth, fueled by innovations in product development that enhance drug delivery and provide better control during the procedure. Furthermore, the increasing preference for non-spherical embolic agents that offer improved flow dynamics and reduced post-embolization syndrome is expected to propel this segment's expansion in the coming years.

Catheters:

Catheters are essential for the administration of chemotherapy drugs and embolic agents during TACE procedures. The demand for specialized catheters designed for interventional radiology is increasing, as they provide greater precision and flexibility during embolization. Innovations in catheter design, including the development of coaxial systems and microcatheters, are enhancing the ability to reach smaller, more distal tumors. The market for catheters in TACE is expected to grow substantially, driven by the increasing number of TACE procedures being performed globally. As healthcare providers continue to adopt advanced catheter technologies, this segment is likely to witness significant advancements, improving patient outcomes and procedural efficacy.

Guidewires:

Guidewires are critical components in the TACE procedure, offering support and access to the targeted vessels for catheter navigation. The growing adoption of advanced guidewire technologies, such as hydrophilic and safety guidewires, is promoting the safe and efficient performance of TACE procedures. The market for guidewires is on an upward trajectory, driven by an increasing number of TACE interventions and a rising prevalence of liver diseases. Innovations in guidewire design that enhance navigability and reduce complications are contributing to the growth of this segment. As interventional radiology continues to evolve, the importance of reliable guidewires in TACE procedures remains paramount, ensuring optimal targeting and delivery of therapeutic agents.

Others:

This segment includes various ancillary products and tools that support the TACE procedure, such as imaging contrast agents and other specialized devices. While this segment may not represent the largest share of the market, it is essential for ensuring the success of TACE procedures. The integration of advanced imaging technologies and tools that improve procedural accuracy is driving growth in this segment. As TACE becomes more widely adopted for liver cancer treatment, the demand for complementary products is expected to rise, supporting the overall TACE market growth.

By Application

Hepatocellular Carcinoma:

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and represents the largest application segment in the TACE market. TACE is often used as a curative treatment option for patients with intermediate-stage HCC who are not candidates for surgical resection or liver transplantation. The efficacy of TACE in reducing tumor size and improving patient survival rates has led to its widespread adoption in clinical practice. With the increasing incidence of HCC globally, particularly in regions with high hepatitis virus prevalence, the demand for TACE procedures targeted at HCC is expected to grow significantly. Ongoing research and clinical trials aimed at optimizing TACE protocols for HCC will further enhance treatment outcomes and market growth.

Liver Metastases:

TACE is increasingly being utilized in the management of liver metastases originating from other primary cancers, such as colorectal and breast cancer. This application segment is gaining traction as healthcare professionals recognize the potential of TACE to effectively control metastases in the liver, which is a common site for secondary tumor growth. The ability to deliver high doses of chemotherapy directly to the tumor while minimizing systemic exposure makes TACE an attractive option. As the prevalence of liver metastases continues to rise, coupled with advancements in TACE techniques, this segment is expected to experience significant market growth in the coming years.

Cholangiocarcinoma:

Cholangiocarcinoma, a rare form of liver cancer, is increasingly being treated with TACE as a palliative measure. The complexity of treating this cancer type, which often presents at an advanced stage, necessitates innovative approaches like TACE. The growing understanding of TACE's role in managing cholangiocarcinoma has led to an uptick in its adoption. As clinical evidence supporting TACE's efficacy for cholangiocarcinoma accumulates, this application segment is expected to expand, offering new opportunities for patient management and enriching the overall TACE market.

Neuroendocrine Tumors:

Neuroendocrine tumors that metastasize to the liver can also be treated effectively using TACE. This application segment, although smaller in comparison to HCC and liver metastases, is gaining attention as more oncologists recognize the potential benefits of TACE in managing these types of tumors. The unique vascularity of neuroendocrine tumors makes them suitable candidates for this treatment modality. Ongoing research and clinical trials are expected to shed light on the effectiveness of TACE specifically for neuroendocrine tumors, potentially increasing its adoption in clinical practice.

Others:

This segment encompasses various other applications of TACE, which may include lesser-known types of liver tumors and conditions. While it may not command a significant market share, its relevance cannot be overlooked as the scope of TACE expands beyond traditional indications. As awareness and understanding of TACE grow among healthcare providers, there is potential for increased utilization in other applications, driven by ongoing research and clinical findings that highlight its versatility and effectiveness.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for TACE procedures, serving as the main setting for interventional radiology. The presence of advanced imaging technologies, skilled interventional radiologists, and comprehensive cancer care programs in hospitals facilitates the successful execution of TACE. As the demand for TACE grows, hospitals are increasingly investing in state-of-the-art equipment and training for personnel to optimize patient outcomes. The hospital segment is expected to dominate the TACE market due to its established infrastructure and the ability to provide multidisciplinary care for cancer patients.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming an increasingly important distribution channel for TACE due to their focus on outpatient procedures. The rise of minimally invasive techniques has led to a shift towards outpatient care, making ASCs an attractive alternative for patients undergoing TACE. These centers offer a more convenient and cost-effective option for patients while maintaining high-quality care. As patient preferences shift towards outpatient settings and advancements in TACE technology continue, the ASC segment is poised for significant growth within the TACE market.

Specialty Clinics:

Specialty clinics specializing in oncology or interventional radiology are also contributing to the TACE distribution landscape. These clinics often provide targeted therapies and personalized treatment plans for patients with liver cancer, making them valuable players in the TACE market. The increasing number of specialty clinics and their focus on innovative cancer treatments are facilitating patient access to TACE procedures. As more patients seek specialized care for liver cancer, the role of specialty clinics in the TACE market is expected to expand, offering alternative pathways for treatment delivery.

Others:

This segment includes various other distribution channels, such as outpatient departments within larger healthcare facilities and telehealth platforms that facilitate patient consultations and referrals for TACE. Although smaller in scale, these channels play a vital role in ensuring that patients receive timely access to TACE procedures. The ongoing evolution of healthcare delivery models and the increasing use of technology to enhance patient care may further boost the significance of these alternative distribution channels in the TACE market.

By Ingredient Type

Doxorubicin:

Doxorubicin is one of the most commonly used chemotherapy drugs in TACE procedures, renowned for its effectiveness in treating a variety of cancer types, including liver tumors. Its ability to induce apoptosis in cancer cells makes it a cornerstone in the management of hepatocellular carcinoma. The demand for doxorubicin in the TACE market is driven by its established track record and favorable clinical outcomes. Ongoing research into optimizing doxorubicin formulations and delivery methods is expected to enhance its efficacy further, solidifying its position as a leading ingredient in the TACE market.

Cisplatin:

Cisplatin is another important chemotherapy agent utilized in the TACE procedure, particularly for liver tumors that show sensitivity to platinum-based therapies. Its unique mechanism of action disrupts DNA replication in cancer cells, making it effective in targeting aggressive malignancies. The cisplatin segment is expected to grow, driven by increased clinical evidence supporting its use in combination with other agents. The development of novel cisplatin formulations that reduce side effects while maintaining efficacy is likely to contribute to its sustained demand in TACE.

Mitomycin C:

Mitomycin C is a potent chemotherapy drug known for its selective action against certain tumor types, including liver cancers. Its role in TACE is growing as clinicians explore ways to enhance treatment efficacy through combination therapies. The increasing recognition of mitomycin C's potential in TACE procedures is driving market interest, particularly as more research identifies optimal dosing strategies and combinations with other therapeutic agents. As clinical studies continue to evaluate its effectiveness, mitomycin C is expected to gain further traction in the TACE market.

Ethiodized Oil:

Ethiodized oil is a crucial component in TACE, serving as a contrast agent that enhances visualization during the procedure, as well as a drug carrier for hydrophobic chemotherapy agents. Its ability to selectively accumulate in liver tumors, providing localized chemotherapy while limiting systemic exposure, makes it vital for successful TACE outcomes. The demand for ethiodized oil is expected to rise as TACE procedures become more prevalent, with ongoing research focused on improving its formulation and delivery techniques. The segment is poised for growth as awareness of its benefits becomes more widespread among interventional radiologists.

Others:

This segment encompasses a variety of other ingredients used in TACE procedures, including novel drug formulations and combination therapies that aim to enhance treatment efficacy. As the field of interventional oncology evolves, the exploration of new compounds and alternative drug delivery systems will play a significant role in shaping the TACE market. The rise in clinical trials investigating the use of emerging agents and their integration into standard TACE protocols is likely to foster innovation and expand treatment options for patients.

By Region

The Transarterial Chemoembolization market is witnessing significant growth across various regions, driven by the increasing prevalence of liver cancer and the adoption of advanced interventional radiology techniques. North America currently dominates the market, accounting for over 40% of the global share. This is attributed to the presence of a well-established healthcare infrastructure, high awareness of TACE among healthcare professionals, and a growing number of specialized cancer centers. Moreover, the increasing investment in cancer research and the availability of advanced technologies support the robust growth of TACE in this region. It is projected that North America will continue to maintain its lead with a CAGR of 11.8% through 2035.

In contrast, the Asia Pacific region is emerging as a crucial area for TACE market growth, primarily due to the rising incidence of liver cancer in countries such as China and Japan. This region is expected to experience the highest growth rate, with a projected CAGR of 14.6% through 2035. The increasing awareness of TACE as a treatment option, coupled with improvements in healthcare access and interventional radiology capabilities, is driving the expansion of TACE procedures in Asia Pacific. Meanwhile, Europe is also witnessing growth, but its market share is slightly lower compared to North America and Asia Pacific, driven by varying healthcare regulations and levels of technology adoption.

Opportunities

The growing demand for minimally invasive procedures presents a unique opportunity for the TACE market. As patients increasingly seek options that minimize recovery time and reduce hospital stays, TACE's less invasive nature compared to traditional surgeries positions it as an attractive alternative. The ongoing advancements in interventional radiology techniques and the development of novel embolic agents are likely to enhance the efficacy of TACE, making it a more appealing choice for patients and healthcare providers. Furthermore, with an increasing focus on personalized medicine, the customization of TACE protocols based on tumor characteristics and patient profiles can further optimize treatment outcomes, capturing a broader patient demographic.

Additionally, the expansion of telemedicine and remote healthcare services offers significant opportunities for the TACE market. As healthcare systems around the world embrace digital solutions, the ability to provide consultations, follow-ups, and even pre-procedural evaluations through telehealth platforms can increase patient access to TACE procedures. This not only facilitates timely treatment for patients but also allows healthcare providers to reach underserved populations. Embracing these digital innovations can significantly enhance the market's growth potential, paving the way for broader acceptance and utilization of TACE in cancer treatment.

Threats

Despite the growth potential of the Transarterial Chemoembolization market, several threats could hinder its progress. One significant challenge is the rising competition from alternative treatment modalities such as radiofrequency ablation, targeted therapy, and immunotherapy, which may offer comparable or superior efficacy for certain liver tumors. As these alternative treatments continue to evolve and improve, they may divert patients away from TACE, impacting market share. Furthermore, the availability of advanced technologies and new therapies may increase treatment costs, potentially leading patients and healthcare systems to consider more cost-effective options. The need for continuous innovation and adaptation to maintain TACE's relevance in a rapidly changing oncology landscape is crucial for sustaining market growth.

Regulatory challenges also pose a threat to the TACE market. The approval processes for new drugs and medical devices can be lengthy and complex, delaying the introduction of innovative TACE components and potentially stifling market growth. Additionally, the variability in regulations across different countries can complicate the distribution and adoption of TACE technologies, limiting their accessibility to healthcare providers. As the market expands globally, navigating these regulatory hurdles will be essential for companies seeking to capitalize on the growing demand for TACE.

Competitor Outlook

• Boston Scientific Corporation
• Terumo Medical Corporation
• Merit Medical Systems, Inc.
• Cook Medical Incorporated
• AngioDynamics, Inc.
• Medtronic plc
• Philips Healthcare
• Surefire Medical, Inc.
• Biocompatibles UK Ltd. (a BTG International Group Company)
• W.L. Gore & Associates, Inc.
• iVascular S.L.U.
• Sphere Medical Holding plc
• Halyard Health, Inc.
• Kangdi Medical
• Abbot Laboratories

The competitive landscape of the Transarterial Chemoembolization market is characterized by a mix of established players and emerging innovators. Major companies such as Boston Scientific Corporation and Terumo Medical Corporation are leading the market, providing a range of solutions that enhance the efficacy of TACE procedures. These companies are heavily invested in research and development, focusing on the creation of advanced embolic agents, innovative catheter technologies, and specialized chemotherapy formulations to meet the evolving needs of clinicians and patients. The competitive intensity is further heightened by the presence of smaller firms and startups, which are introducing disruptive technologies and novel treatment approaches that challenge established norms in TACE.

In addition to product innovation, companies are increasingly adopting strategic collaborations and partnerships to strengthen their market position. This includes alliances with academic institutions for research purposes, as well as partnerships with healthcare providers to expand their reach in underserved markets. For instance, companies like AngioDynamics have engaged in collaborations to enhance their product offerings and improve patient outcomes. This trend is expected to continue, as companies recognize the value of leveraging external expertise and resources to accelerate innovation and drive growth in the TACE market.

Some notable players, such as Medtronic and Philips Healthcare, are also focusing on expanding their geographical presence in emerging markets where the prevalence of liver cancer is rising. These companies aim to capitalize on the growing demand for TACE procedures by establishing regional offices and manufacturing facilities. Such strategic initiatives not only enhance product availability but also allow for localized research efforts that cater to the specific needs of different patient populations. As the competitive landscape evolves, maintaining a focus on innovation, strategic partnerships, and geographical expansion will be critical for sustained success in the TACE market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Kangdi Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 iVascular S.L.U.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Abbot Laboratories
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Philips Healthcare
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AngioDynamics, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Halyard Health, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Surefire Medical, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Cook Medical Incorporated
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Sphere Medical Holding plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Terumo Medical Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Merit Medical Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 W.L. Gore & Associates, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Biocompatibles UK Ltd. (a BTG International Group Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Transarterial Chemoembolization Market, By Application
    • 6.1.1 Hepatocellular Carcinoma
    • 6.1.2 Liver Metastases
    • 6.1.3 Cholangiocarcinoma
    • 6.1.4 Neuroendocrine Tumors
    • 6.1.5 Others
  • 6.2 Transarterial Chemoembolization Market, By Product Type
    • 6.2.1 Chemotherapy Drugs
    • 6.2.2 Embolic Agents
    • 6.2.3 Catheters
    • 6.2.4 Guidewires
    • 6.2.5 Others
  • 6.3 Transarterial Chemoembolization Market, By Ingredient Type
    • 6.3.1 Doxorubicin
    • 6.3.2 Cisplatin
    • 6.3.3 Mitomycin C
    • 6.3.4 Ethiodized Oil
    • 6.3.5 Others
  • 6.4 Transarterial Chemoembolization Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Transarterial Chemoembolization Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Transarterial Chemoembolization market is categorized based on

By Product Type

• Chemotherapy Drugs
• Embolic Agents
• Catheters
• Guidewires
• Others

By Application

• Hepatocellular Carcinoma
• Liver Metastases
• Cholangiocarcinoma
• Neuroendocrine Tumors
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Ingredient Type

• Doxorubicin
• Cisplatin
• Mitomycin C
• Ethiodized Oil
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Terumo Medical Corporation
• Merit Medical Systems, Inc.
• Cook Medical Incorporated
• AngioDynamics, Inc.
• Medtronic plc
• Philips Healthcare
• Surefire Medical, Inc.
• Biocompatibles UK Ltd. (a BTG International Group Company)
• W.L. Gore & Associates, Inc.
• iVascular S.L.U.
• Sphere Medical Holding plc
• Halyard Health, Inc.
• Kangdi Medical
• Abbot Laboratories